{"id":"W3152739953","doi":"10.1016/j.clgc.2021.04.008","title":"Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors","year":2021,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"ca_institutions":"McMaster University","funders":"Janssen Pharmaceuticals; EMD Serono; Genentech; National Institutes of Health; Bavarian Nordic; Bayer Schering; Astellas Pharma; Eisai; Cancer Research UK; GlaxoSmithKline; Virginia Marine Resources Commission; Advanced Accelerator Applications; Bayer Fund; Clovis Oncology; Meso Scale Diagnostics; Les Laboratories Pierre Fabre; Jounce Therapeutics; Merck Sharp and Dohme; Genzyme; National Institute on Handicapped Research; Exelixis; Sanofi; Novartis; Merck; Heron Therapeutics; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca; Roche; Astellas Pharma US; Boehringer Ingelheim; Amgen; Pfizer","keywords":"Medicine; Nivolumab; Internal medicine; Pembrolizumab; Durvalumab; Oncology; Atezolizumab; Metastatic Urothelial Carcinoma; Carboplatin; Cisplatin; Response Evaluation Criteria in Solid Tumors; Retrospective cohort study; Urology; Bladder cancer; Urothelial carcinoma; Cancer; Chemotherapy; Progressive disease; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003814125,0.000140571,0.0004966756,0.0002717579,0.0003057329,0.0008095399,0.0002706799,0.0003822892,0.001296284],"category_scores_gemma":[0.001818389,0.0001094378,0.0006496856,0.000481217,0.0002486667,0.0005682741,0.0003808961,0.0006578979,0.0001815555],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004584381,"about_ca_system_score_gemma":0.0003919184,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001409599,"about_ca_topic_score_gemma":0.002283809,"domain_scores_codex":[0.9997475,0.00005748122,0.00003157654,0.00005583323,0.00003420081,0.00007343978],"domain_scores_gemma":[0.9990155,0.0001984624,0.000410805,0.00004173254,0.00006463329,0.0002689738],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.007272718,0.000289192,0.9742271,0.00007540866,0.0002726243,0.0004925657,0.0001164708,0.0006474574,0.000745781,0.000131893,0.0009012455,0.01482754],"study_design_scores_gemma":[0.0002631244,0.002145634,0.9942501,0.00003238099,0.0002534658,0.0007140735,0.00024105,0.0006779031,0.0001702354,0.0002626541,0.0009745629,0.00001476136],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9968724,0.0009866809,0.00005498985,0.0001927699,0.00002107059,0.00001176437,0.0007438336,0.000004081694,0.001112491],"genre_scores_gemma":[0.9985427,0.0002123488,0.00001649485,0.00008064156,0.00001625648,0.00000590755,0.0009015326,0.000001283347,0.0002228212],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001409599,"threshold_uncertainty_score":0.004336476,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03517358340460927,"score_gpt":0.3511806430000108,"score_spread":0.3160070595954015,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}